Accessibility Menu
 
Silence Therapeutics Plc logo

Silence Therapeutics Plc

(NASDAQ) SLN

Current Price$5.89
Market Cap$280.57M
Since IPO (2020)-70%
5 Year-74%
1 Year+106%
1 Month+5%

Silence Therapeutics Plc Financials at a Glance

Market Cap

$280.57M

Revenue (TTM)

$559.00K

Net Income (TTM)

$88.61M

EPS (TTM)

$-1.88

P/E Ratio

-3.16

Dividend

$0.00

Beta (Volatility)

0.63 (Low)

Price

$5.89

Volume

46,325

Open

$5.43

Previous Close

$5.89

Daily Range

$5.43 - $5.90

52-Week Range

$1.97 - $7.91

SLN News

SLN: Motley Fool Moneyball Superscore

60

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Silence Therapeutics Plc

Industry

Biotechnology

Employees

88

CEO

Iain Gladstone Ross

Headquarters

London, W14 8TH, GB

SLN Financials

Key Financial Metrics (TTM)

Gross Margin

62%

Operating Margin

-163%

Net Income Margin

-159%

Return on Equity

0%

Return on Capital

-77%

Return on Assets

-67%

Earnings Yield

-31.65%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$280.57M

Shares Outstanding

47.23M

Volume

46.33K

Short Interest

0.00%

Avg. Volume

292.18K

Financials (TTM)

Gross Profit

$344.00K

Operating Income

$89.75M

EBITDA

$60.80M

Operating Cash Flow

$62.27M

Capital Expenditure

$55.00K

Free Cash Flow

$62.33M

Cash & ST Invst.

$85.11M

Total Debt

$160.00K

Silence Therapeutics Plc Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$34.00K

-99.9%

Gross Profit

$22.00K

-99.9%

Gross Margin

64.71%

N/A

Market Cap

$280.57M

N/A

Market Cap/Employee

$2.42M

N/A

Employees

116

N/A

Net Income

$11.77M

-183.0%

EBITDA

$9.28M

-229.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$85.27M

-42.1%

Accounts Receivable

$18.27M

-32.1%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-67.42%

N/A

Return on Invested Capital

-77.30%

N/A

Free Cash Flow

$17.34M

+30.4%

Operating Cash Flow

$17.29M

+30.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ACIUAC Immune S.A.
$2.76-1.08%
AMRNAmarin Corporation plc
$14.74+0.68%
KYTXKyverna Therapeutics, Inc.
$8.87+1.14%
LXEOLexeo Therapeutics, Inc. Common Stock
$5.72+0.88%

Trending Stocks

Symbol / CompanyPricePrice Chg
SKYQSky Quarry
$5.10+1.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.37-0.11%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.33+0.00%
NOKNokia
$8.82+0.07%

Questions About SLN

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.